Vertically-integrated cannabis company Flower One has now completed conversion of its commercial greenhouse in North Las Vegas, making it capable of producing more than 62,500 kg of dried flower per year, by far the largest cannabis cultivation operation in the state.
In a client update Thursday, McLeish says Nevada’s climate, with its 290 days of sunlight per year and more than ten hours of sunlight per day, plus its dry heat and low humidity, is ideal for growing cannabis in a greenhouse environment.
The analyst says the scale of FONE’s operations should result in an all-in cash cost per gram of less than $1.00, which he says compares very favourably to competitors that operate smaller-scale greenhouses and indoor operations. Once Flower One reaches scale, McLeish says that it should be generating EBITDA margins above 30 per cent. (All figures in US dollars unless noted otherwise.)
“We had been applying a 10x EV/EBITDA multiple to value Flower One to take into account the execution risk associated with building out a successful large scale greenhouse operation. However, this execution risk has been mitigated as evidenced by our recent tour of the NLV Greenhouse. Additionally, the closing of the C$57.5 million convertible debenture financing and the recently announced licensing agreements and brand partnerships will help to underpin our financial forecasts through 2020. As a result, we are increasing our EV/EBITDA target multiple to 11x from 10x,” says McLeish.
The analyst is calling for fiscal 2019 revenue and EBITDA of $134.9 million and $45.1 million, respectively, and fiscal 2020 revenue and EBITDA of $251.1 million and $90.6 million, respectively. McLeish is maintaining his “Buy” rating and moving his target price from C$5.50 to C$6.50, which represented a projected return of 117 per cent at the time of publication.
On Oct. 22, Paradigm Capital analyst Marvin Wolff raised his target on CHAR Technologies (CHAR Technologies Stock Quote, Chart, News,… [Read More]
Stifel analyst Justin Keywood maintained his “Buy” rating and $44.00 target on ATS Corporation (ATS Corporation Stock Quote, Chart, News,… [Read More]
Markets have been choppy, but billionaire investor Bill Ackman sees the potential for a much stronger backdrop in 2027. Speaking… [Read More]
Beacon Securities analyst Russell Stanley reiterated his “Buy” rating and $1.00 target on Atlas Engineered Products (Atlas Engineered Products Stock… [Read More]
Roth Capital Partners analyst Boobalan Pachaiyappan initiated coverage of Atrium Therapeutics (Atrium Therapeutics, Stock Quote, Chart, News, Analysts, Financials NASDAQ:RNA)… [Read More]
Goodreid Investment Counsel president and CEO Gordon Reid says Texas Instruments (Texas Instruments Stock Quote, Chart, News, Analysts, Financials NASDAQ:TXN)… [Read More]